Cargando…

mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development

After the genome sequence of SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) was published and the number of infected people began to increase rapidly, many global companies began to develop a vaccine. Almost all known approaches to vaccine design were applied for this purpose,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilyichev, A.A., Orlova, L.A., Sharabrin, S.V., Karpenko, L.I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094037/
https://www.ncbi.nlm.nih.gov/pubmed/33959697
http://dx.doi.org/10.18699/VJ20.676
_version_ 1783687938224160768
author Ilyichev, A.A.
Orlova, L.A.
Sharabrin, S.V.
Karpenko, L.I.
author_facet Ilyichev, A.A.
Orlova, L.A.
Sharabrin, S.V.
Karpenko, L.I.
author_sort Ilyichev, A.A.
collection PubMed
description After the genome sequence of SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) was published and the number of infected people began to increase rapidly, many global companies began to develop a vaccine. Almost all known approaches to vaccine design were applied for this purpose, including inactivated viruses, mRNA and DNA-vaccines, vaccines based on various viral vectors, synthetically generated peptides and recombinant proteins produced in cells of insects and mammals. This review considers one of the promising vaccine platforms based on messenger RNA. Until recent years, mRNA-vaccination was out of practical implementation due to high sensitivity to nuclease degradation and consequent instability of drugs based on mRNA. Latest technological advances significantly mitigated the problems of low immunogenicity, instability, and difficulties in RNA-vaccine delivery. It is worth noting that mRNA-vaccines can efficiently activate both components of the immune system, i. e. T-cell and humoral responses. The essential advantage of mRNAvaccines includes fast, inexpensive, scalable and uniform production providing a large output of desirable products in vitro. Synthesis and purification processes significantly simplify the process technology of mRNA drugs with injectable purity. Thus, mRNA production via in vitro transcription is more advantageous as compared with DNA-vaccines since it is a chemical process without the use of cells. mRNA techniques make it possible to pass all the phases of vaccine development much faster in comparison with the production of vaccines based on inactivated viruses or recombinant proteins. This property is critically important when designing vaccines against viral pathogens as the main problem of disease control includes a time gap between an epidemic and vaccine development. This paper discusses studies on the development of vaccines against coronaviruses including SARS-CoV-2 with special attention to the mRNA technique.
format Online
Article
Text
id pubmed-8094037
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-80940372021-05-05 mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development Ilyichev, A.A. Orlova, L.A. Sharabrin, S.V. Karpenko, L.I. Vavilovskii Zhurnal Genet Selektsii Review After the genome sequence of SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) was published and the number of infected people began to increase rapidly, many global companies began to develop a vaccine. Almost all known approaches to vaccine design were applied for this purpose, including inactivated viruses, mRNA and DNA-vaccines, vaccines based on various viral vectors, synthetically generated peptides and recombinant proteins produced in cells of insects and mammals. This review considers one of the promising vaccine platforms based on messenger RNA. Until recent years, mRNA-vaccination was out of practical implementation due to high sensitivity to nuclease degradation and consequent instability of drugs based on mRNA. Latest technological advances significantly mitigated the problems of low immunogenicity, instability, and difficulties in RNA-vaccine delivery. It is worth noting that mRNA-vaccines can efficiently activate both components of the immune system, i. e. T-cell and humoral responses. The essential advantage of mRNAvaccines includes fast, inexpensive, scalable and uniform production providing a large output of desirable products in vitro. Synthesis and purification processes significantly simplify the process technology of mRNA drugs with injectable purity. Thus, mRNA production via in vitro transcription is more advantageous as compared with DNA-vaccines since it is a chemical process without the use of cells. mRNA techniques make it possible to pass all the phases of vaccine development much faster in comparison with the production of vaccines based on inactivated viruses or recombinant proteins. This property is critically important when designing vaccines against viral pathogens as the main problem of disease control includes a time gap between an epidemic and vaccine development. This paper discusses studies on the development of vaccines against coronaviruses including SARS-CoV-2 with special attention to the mRNA technique. The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences 2020-11 /pmc/articles/PMC8094037/ /pubmed/33959697 http://dx.doi.org/10.18699/VJ20.676 Text en Copyright © AUTHORS https://creativecommons.org/licenses/by/2.5/This work is licensed under a Creative Commons Attribution 4.0 License
spellingShingle Review
Ilyichev, A.A.
Orlova, L.A.
Sharabrin, S.V.
Karpenko, L.I.
mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
title mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
title_full mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
title_fullStr mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
title_full_unstemmed mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
title_short mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
title_sort mrna technology as one of the promising platforms for the sars-cov-2 vaccine development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094037/
https://www.ncbi.nlm.nih.gov/pubmed/33959697
http://dx.doi.org/10.18699/VJ20.676
work_keys_str_mv AT ilyichevaa mrnatechnologyasoneofthepromisingplatformsforthesarscov2vaccinedevelopment
AT orlovala mrnatechnologyasoneofthepromisingplatformsforthesarscov2vaccinedevelopment
AT sharabrinsv mrnatechnologyasoneofthepromisingplatformsforthesarscov2vaccinedevelopment
AT karpenkoli mrnatechnologyasoneofthepromisingplatformsforthesarscov2vaccinedevelopment